Abstract
Conventionally, cardiac biomarkers are recognized as an essential tool to investigate the presence or progression of various cardiovascular diseases. However, in recent years, data from several clinical trials have successfully sorted out the utility of cardiac biomarkers in diseases that are not primarily regarded as “cardiac diseases,” especially neurological diseases. Results of freshly published trials have endorsed the use of cardiac biomarkers in various forms of stroke and dementia, including Alzheimer’s disease. Alzheimer’s disease is also one of the other CNS conditions where measuring cardiac biomarkers have been found to be useful. Cardiac biomarkers can be helpful in two ways. Firstly, to assess the secondary involvement of the heart during the progression of the primary disease. Secondly, they can be useful in the diagnosis and prognosis of the primary condition itself. In this short review, we have collected encouraging results from recent studies that show the importance of the most widely recognized cardiac biomarkers in two of the most prominent neurological diseases of the current world, i.e., stroke and dementia.
Keywords: Cardiac biomarker, BNP, troponin, Alzheimer's disease, stroke, pneumonia.
CNS & Neurological Disorders - Drug Targets
Title:Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
Volume: 20 Issue: 8
Author(s): Shahzad Khan*Mohammad Amjad Kamal
Affiliation:
- Department of Pathophysiology, Wuhan University School of Medicine, Hubei, Wuhan 430071,China
Keywords: Cardiac biomarker, BNP, troponin, Alzheimer's disease, stroke, pneumonia.
Abstract: Conventionally, cardiac biomarkers are recognized as an essential tool to investigate the presence or progression of various cardiovascular diseases. However, in recent years, data from several clinical trials have successfully sorted out the utility of cardiac biomarkers in diseases that are not primarily regarded as “cardiac diseases,” especially neurological diseases. Results of freshly published trials have endorsed the use of cardiac biomarkers in various forms of stroke and dementia, including Alzheimer’s disease. Alzheimer’s disease is also one of the other CNS conditions where measuring cardiac biomarkers have been found to be useful. Cardiac biomarkers can be helpful in two ways. Firstly, to assess the secondary involvement of the heart during the progression of the primary disease. Secondly, they can be useful in the diagnosis and prognosis of the primary condition itself. In this short review, we have collected encouraging results from recent studies that show the importance of the most widely recognized cardiac biomarkers in two of the most prominent neurological diseases of the current world, i.e., stroke and dementia.
Export Options
About this article
Cite this article as:
Khan Shahzad *, Kamal Amjad Mohammad , Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations, CNS & Neurological Disorders - Drug Targets 2021; 20 (8) . https://dx.doi.org/10.2174/1871527319666201005171003
DOI https://dx.doi.org/10.2174/1871527319666201005171003 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases
Current Pharmaceutical Design Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design L-Type Calcium Channels
Current Pharmaceutical Design Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?
Current Pharmaceutical Design Bradykinin Receptors in Ischemic Injury
Current Neurovascular Research Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets Effect of SDF-1 α on Endogenous Mobilized and Transplanted Stem Cells in Regeneration after Myocardial Infarction
Current Pharmaceutical Design Unconventional Players on the Striated Muscle Field: microRNAs, Signaling Pathways and Epigenetic Regulators
Current Stem Cell Research & Therapy Translational Applications of Tissue Engineering in Cardiovascular Medicine
Current Pharmaceutical Design Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors
Current Cancer Drug Targets Cellular Strategies to Combat Protein Misfolding: Intricate Role of Hsp70 in Stress Management
Current Chemical Biology New Insights in Research About Acute Ischemic Myocardial Injury and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cellular Therapy for Myocardial Repair
Current Cardiology Reviews Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets Perspective on the Role of Four Beta-blockers in Heart Failure
Current Reviews in Clinical and Experimental Pharmacology Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Current Genomics Refined Echocardiographic Assessment and Contemporary Medical Treatment of Obstructive Hypertrophic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Sex Differences in Alcohol Use Disorder
Current Medicinal Chemistry Perinatal Heart Programming: Long-term Consequences
Current Medicinal Chemistry Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry